These are top 10 stocks traded on the Robinhood UK platform in July
On Monday, Citizens JMP maintained a positive outlook on Evolent Health (NYSE:EVH) shares, reiterating a Market Outperform rating and a $13.00 price target. The firm’s analysts highlighted Evolent Health’s effective recontracting initiatives, which are anticipated to bolster adjusted EBITDA by $115 million. This improvement comes at a time when the company is navigating an environment of rising oncology costs. According to InvestingPro data, EVH’s current stock price of $8.98 represents a significant discount from its 52-week high of $33.63, suggesting potential upside opportunity.
The analysts at Citizens JMP expressed confidence in Evolent Health’s management, noting that the company has taken decisive steps to shield its operations from external pressures. These measures are expected to lead to more stable and predictable profits for the healthcare company. InvestingPro analysis reveals management’s commitment through aggressive share buybacks, while the company maintains a solid financial health score of 2.56, rated as "GOOD" by InvestingPro’s comprehensive evaluation system.
Evolent Health’s strategic focus on recontracting is part of its broader effort to optimize financial performance. The company’s ability to renegotiate contracts effectively is seen as a key driver for the anticipated EBITDA increase. With current EBITDA at $94 million and analyst targets ranging from $12 to $20, InvestingPro subscribers can access 6 additional key insights about EVH’s growth potential through the platform’s exclusive Pro Research Report.
The positive assessment by Citizens JMP underscores the belief that Evolent Health’s internal strategies are well-positioned to mitigate potential market challenges. The company’s proactive approach in managing its business is recognized as a significant factor in its potential for sustained financial growth.
Investors and stakeholders in Evolent Health can look to the reaffirmed price target and rating as indicators of the company’s current financial trajectory. The guidance from Citizens JMP suggests that Evolent Health is on track to achieve its financial goals, despite the pressures of a high-cost trend in oncology care.
In other recent news, Evolent Health reported fourth-quarter results that did not meet analyst expectations, with adjusted earnings per share of -$0.02, falling short of the projected $0.07. The company’s revenue for the quarter was $646.5 million, slightly below the anticipated $652.2 million, but it still marked a 16.3% year-over-year increase. For the full year 2024, Evolent’s revenue grew by 30.1% to $2.55 billion, but its forecast for 2025 revenue, between $2.06 billion and $2.11 billion, was below the expected $2.42 billion. Despite these challenges, Evolent maintained 100% partner contract retention and announced two new revenue agreements.
Analyst firm Citizens JMP raised Evolent Health’s stock target to $13, maintaining a Market Outperform rating, citing confidence in the management’s ability to navigate challenges. Meanwhile, Piper Sandler adjusted its price target for Evolent Health to $16, down from $17, while keeping an Overweight rating, noting the company’s strong bookings and customer retention. Piper Sandler expressed optimism about Evolent’s future prospects, despite the slight reduction in price target.
In a separate analysis, KeyBanc Capital Markets discussed a hypothetical acquisition of Evolent’s Medicare Shared Savings Program business by Privia Health. While the acquisition appears unlikely, KeyBanc highlighted potential financial benefits for both companies, including improved leverage ratios for Evolent and strategic opportunities for Privia Health. These developments reflect ongoing evaluations and strategic considerations within the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.